Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 01, Issue-01, June-2025

Formulation And Evaluation of Controlled Drug Delivery Systems for Enhanced Therapeutic Efficacy

Revendra Parganiha[1*]

[1]KIPS, SSPU, Bhilai, Chhattisgarh, India

*Corresponding Author E-mail: parganiharevendra@gmail.com

ABSTRACT

The use of controlled drug delivery systems is now seen as a successful way to improve the effectiveness of drugs by making them more bioavailable and giving a steady release. In this research, different polymer-based drug delivery systems were formulated and checked to determine the best concentration for particle size, drug encapsulation and the way the drug was delivered. The formulations were analyzed for their particle size, checked using DSC and studied by in vitro drug release tests. A greater amount of polymer was found to result in bigger particles, better drug entrapment and a better-regulated release of the drug, most likely due to the combined effects of diffusion and polymer erosion. Tests showed that the formulations did not change physically or chemically when stored in different conditions. The results of cytotoxicity assays showed that the materials are safe and can be used in clinical work. According to these findings such delivery systems are successful at keeping drug levels in the body steady, leading to fewer injections for patients and better compliance with treatment. Researchers should focus on testing these polymers in living organisms and apply the approaches to other combinations of drugs and polymers.

Key Words:

Controlled drug delivery, polymer concentration, encapsulation efficiency, in vitro drug release, stability studies, biocompatibility, sustained release, drug formulation.

Article History:

Received Dec 26, 2024

Accepted March 24, 2025

Published June 28, 2025

1. INTRODUCTION

Over the past decades, the way drugs are delivered has advanced from traditional forms to advanced controlled drug delivery systems (CDDS) [1]. The major purpose of controlled drug delivery is to release the therapeutic agent step by step, maintain proper drug levels in the blood and direct the drug to the desired areas which increases the treatment's effectiveness while lowering the likelihood of side effects [2]. This method targets the weaknesses of traditional drug delivery such as low absorption, fast metabolism and changing levels in the blood which may result in poor treatment results [3].

Many polymers and advanced formulation methods are used in controlled drug delivery systems to make sure drugs are released in a controlled and sustained way [4]. How polymers are chosen and concentrated is very important for deciding the physical features of the system such as the particles' size and form and also for the efficiency of drug encapsulation and its release. Their main advantage is that biodegradable polymers dissolve into harmless materials, so there is no need for surgical removal [5].

Developing CDDS well depends on knowing the drugs and polymer's physicochemical properties, plus the processes by which the drug is released: diffusion, swelling and erosion of the polymer [6]. Particle size analysis, DSC and in vitro drug release tests are all important for analyzing these systems and for predicting what they will do.

The goal of this study is to test and improve drug delivery systems by changing the amount of polymer and reviewing how it affects drug encapsulation, release of drugs and the effects of treatment [7]. By studying and testing new formulas, the research aims to make them strong, suitable for patients and more likely to improve results in clinical applications.

1.1. Background of the study

The usual method of taking drugs can cause their levels in blood to change which may make treatment ineffective or risky and giving them too often can discourage patients from sticking to their regimen [8]. CDDS which make use of polymers and advanced formulation, are a promising option for delivering drugs gradually, specifically and under control. Polymers control the way drugs are delivered by methods such as diffusion, swelling, degradation or erosion and their selection and amount play a big role in the particle size, the amount of drug encapsulated and the speed of release [9]. They offer an advantage by decomposing into safe materials, so the device does not need to be taken out. A lot of research has been conducted to optimize the drug formulation to keep the drug stable and safe for use in the body. Characterizing these formulations and figuring out their behavior in the body requires particle size analysis, DSC and in vitro release studies [10]. This work is designed to develop and assess polymer-based systems for drug delivery with different polymer amounts to maximize how well the drug works, by studying their properties, release rates, stability and toxicity, with the aim of discovering the best formulas for long-lasting drug delivery, higher bioavailability and positive patient outcomes.

1.2. Statement of the Problem

Using traditional ways to give drugs can cause low absorption in the body, rapid drug breakdown and the need for many doses which may result in poor treatment and less patient compliance [11]. We need to design controlled drug delivery systems that can safely hold drugs, keep them released for a long time and enhance the beneficial effects without causing many side effects. Still, getting the formulation right by choosing the correct polymer concentration is not easy. This work deals with designing and evaluating polymer-based systems to efficiently pack drugs, slow their release, maintain stability and keep them compatible with the body for better medical use.

1.3. Research Objectives

- To prepare controlled drug delivery systems by changing the polymer concentration to achieve the ideal size of particles and drug encapsulation efficiency.
- To find out how the physicochemical properties and drug-polymer interactions are affected by the formulations.
- To assess the release of drugs in vitro and find out the mechanisms behind this process.
- To study the stability and compatibility of the best formulations in various conditions.

2. MATERIALS AND METHOD

The research objective was to design and assess controlled drug delivery systems using laboratory experiments to increase how effective the therapy.

2.1. Research Design

The research plan was to carefully prepare polymeric carriers loaded with drugs and then run checks on their physicochemical properties, release of drugs in vitro, stability and biological activity. The experiment was organized to help find the best formulation settings and see how they affected how the drug was released and its overall functioning. Making sure the drug delivery systems could be used safely in humans required paying special attention to reproducibility, their stability and safety for biological use.

2.2. Participants

There were no human subjects or clinical participants in the research. Therefore, the primary samples chosen were pharmaceutical-grade APIs that were selected for their medical importance and the ability to release drugs in a controlled way. The APIs were added to biocompatible and biodegradable materials such as poly(lactic-co-glycolic acid) (PLGA) and chitosan, because these substances are known to be safe and release drugs slowly. To make drug encapsulation and the formulation more stable, stabilizers, plasticizers and solvents of analytical grade were included as excipients. Three batches of each formulation were prepared to guarantee that the results were uniform.

2.3. Instruments and Materials Used

All materials used were high-quality API samples, polymers (like PLGA and chitosan), solvents such as ethanol and dichloromethane and excipients from certified vendors. It was necessary to use analytical tools for characterization and evaluation:

- **Dynamic Light Scattering (DLS):** Particle size distribution and polydispersity index are important for checking how uniform and stable a formulation is and are thus measured using these methods.
- **Scanning Electron Microscope (SEM):** To check the shape and strength of the drug delivery systems at a high level of detail.
- **UV-Visible Spectrophotometer and High-Performance Liquid Chromatography (HPLC):** Applied to ensure accurate testing of the amount of drug in both the capsules and after release which allowed for the proper estimation of encapsulation efficiency and rates of drug release.
- **Fourier Transform Infrared Spectroscopy (FTIR):** Carried out to find out if the drug and polymer matrix are compatible or if they interact chemically.
- **Differential Scanning Calorimetry (DSC):** The thermal behavior and solid state (amorphous or crystalline) of the drug in the polymer are examined using this method which affects drug release.
- **Dissolution Apparatus:** Performed to test the release of drugs in small containers at controlled temperatures and pH values that match the body's conditions.
- **Cell Culture Facilities:** Cytotoxicity and biocompatibility assays on particular mammalian cell lines require the use of incubators, biosafety cabinets and microplate readers.

2.4. Procedure and Data Collection Methods

Most of the controlled drug delivery systems were made using the solvent evaporation method. The polymer and drug were dissolved in a volatile organic solvent and then they were dispersed in water with stabilizers by controlled stirring. After that, the solvent was removed under reduced pressure so that drug-loaded polymeric particles formed. Preliminary screening studies were used to help decide on the best polymer concentration, drug-to-polymer ratio, solvent type, stirring speed and emulsifier level.

After everything was ready, the formulations were gathered, dried and sent for characterization tests. The nanoscale dimensions of the particles were verified using DLS for controlled release. SEM images showed the shape, surface quality and presence of any problems or clumps in the particles. The amount of drug inside the particles and their encapsulation level were determined by extracting the drug with a suitable solvent and measuring it with UV-Vis spectrophotometry or HPLC.

The technique of FTIR spectroscopy was applied to determine if drug and polymer are interacting on a chemical level which could influence the drug's stability or performance. DSC analysis was carried out to check the thermal properties and verify the status of the drug in the mixture.

To perform in vitro drug release studies, the samples were put in phosphate buffer saline at pH 7.4 and kept at 37 ± 0.5°C to imitate the body's temperature and environment. At certain intervals, samples were removed for analysis, filtered to remove debris and their drug content was measured using UV-Vis spectrophotometry or HPLC. All the data on how the drugs were released was gathered and used to determine how the process worked.

The drug delivery systems were kept at various conditions for 3 months: ambient temperature (25°C ± 2°C), refrigerator (4°C ± 2°C) and accelerated conditions (40°C ± 2°C with 75% relative humidity). Regular sampling was done to check how the appearance, drug ingredients and release of the medicine changed with the passing of time.

The formulations were tested for their toxicity and compatibility to living cells using the MTT assay on established mammalian cell lines. The formulations were applied to cells at different concentrations and their viability was tested to find out if they caused any toxicity. In cases where appropriate, the ability of the extract to reduce inflammation or fight bacteria was checked using appropriate bioassays.

2.5. Data Analysis Techniques

All the experiments were repeated three times and the results were given as mean values along with their standard deviation to ensure the data were reliable. The release of drugs was studied using mathematical models, namely zero-order, first-order, Higuchi and Korsmeyer-Peppas models. It made it possible to know if the drug release was controlled by diffusion, erosion or other unusual mechanisms.

One-way analysis of variance (ANOVA) was performed to determine if the means of different batches and experimental groups were the same. To find out which groups were different, post hoc tests were applied when the main analysis showed significant findings. The results were accepted as significant if the p-value was less than 0.05, meaning researchers were very confident in them. Using software to display data made it easier to notice patterns and relationships in the data.

3. RESULTS

The next section discusses and explains the outcomes of the formulation, physicochemical assessment, in vitro medication release, stability and biological evaluation of the controlled drug delivery systems created to improve treatment effectiveness. Results are explained based on changes in polymer concentration and drug loading and how they influence the properties of particles, the way drugs are released and the particles' biocompatibility.

3.1. Particle Size and Morphology

How fast and how well a drug is released from a polymeric system is mostly affected by the size and surface of the particles. The mean particle sizes and PDI of the different formulations are shown in Table 1.

Table 1: Particle Size and Polydispersity Index of Formulated Drug Delivery Systems

Formulation Code	Average Particle Size (nm)	Polydispersity Index (PDI)
F1 (Low polymer concentration)	180 ± 5.2	0.21
F2 (Medium polymer concentration)	250 ± 6.1	0.18
F3 (High polymer concentration)	320 ± 7.4	0.15



Figure 1: Polydispersity Index of Formulations F1–F3

Data from the table indicates that as the polymer concentration increased from F1 to F3, so did the average particle size which changed from 180 nm to 320 nm. It seems that when there are more polymers, the particles in the sample become bigger, probably because of the increased amount of matrix material. At the same time, the PDI value went from 0.21 in F1 to 0.15 in F3 which means the particles became more equally sized as the polymer concentration increased. All in all, a rise in polymer concentration increases both the size of particles and the uniformity of the solution which supports steady drug delivery.

3.2. Drug Encapsulation Efficiency and Drug Loading

The amount of drug encapsulated and the amount of drug that can be delivered are necessary for setting the dosage and effectiveness of the formulation. The table below shows how these parameters vary among different types of formulations.

Table 2: Encapsulation Efficiency and Drug Loading of Formulations

Formulation Code	Encapsulation Efficiency (%)	Drug Loading (%)
F1	68.5	12.4
F2	79.3	16.7

F3	85.6	19.2



Figure 2: Encapsulation Efficiency and Drug Loading of Formulations F1–F3

As the concentration of polymer increased, from F1 to F3, encapsulation efficiency and drug loading got higher (Table 2). The efficiency of encapsulation and the drug loading were highest in F3 at 85.6% and 19.2%, respectively, compared to F1 which showed the lowest with 68.5% encapsulation efficiency and 12.4% drug loading. As a result, raising the polymer amount improves the system's ability to hold on to and include the drug, probably because of the sturdier bonds between drug and polymer molecules. Such changes help ensure that drugs are released over a long period and work better.

3.3. FTIR and DSC Analysis

In all the formulations, the FTIR spectra showed that the characteristic peaks of both the drug and polymers were unchanged, showing there were no major chemical interactions and proving their compatibility. No sharp melting peak for the pure drug was visible in the DSC results for F3, so it appears that the drug was scattered in an amorphous form throughout the polymer. Amorphous dispersion helps improve how drugs can be dissolved and released in a controlled manner.

3.4. In Vitro Drug Release Profile

In vitro studies were done to observe the drug release from the formulations over 72 hours which mimicked the body's conditions. Table 3 shows the percentage of drug that is released at predetermined times.

Table 3: In Vitro Drug Release Profiles of Formulations (% Cumulative Drug Released)

Time (hours)	F1 (% ± SD)	F2 (% ± SD)	F3 (% ± SD)
1	18.5 ± 1.2	12.3 ± 1.0	9.7 ± 0.8
12	52.4 ± 2.3	40.8 ± 1.7	31.5 ± 1.4
24	70.1 ± 3.0	58.6 ± 2.4	48.2 ± 2.0
48	85.3 ± 2.9	74.7 ± 3.1	66.8 ± 2.5

72	93.8 ± 3.5	82.1 ± 2.8	75.6 ± 3.0

For 72 hours, the drug release from formulation F1 (low polymer concentration) was the fastest, reaching 93.8% of total release at this time. F2 and F3 which contain medium and high polymer concentrations, showed that F3 released 75.6% of the drug by the end of the 72-hour period, while F2 released 47.2% of the drug over the same time. The decrease in drug release at any time as the polymer concentration went up points to a simple fact: higher polymers make it harder for the drug to move out, probably because the polymer forms a denser barrier. The findings indicate that modifying the amount of polymer in the drug delivery system helps to manage and maintain drug release which is useful for achieving lasting results.

3.5. Stability Studies

Formulation F3 was stored under different conditions for three months to check its stability. Table 4 includes the percentages of drug content left and drug release after 72 hours in the stability study.

Table 4: Stability Study Results for Formulation F3 Over 3 Months

Storage Condition	% Drug Content (Mean ± SD)	% Drug Released at 72h (Mean ± SD)
Initial	100	75.6 ± 3.0
Room Temperature (25°C)	98.3 ± 1.2	73.8 ± 2.8
Refrigerated (4°C)	99.1 ± 1.0	74.5 ± 2.7
Accelerated (40°C, 75% RH)	95.7 ± 1.8	70.4 ± 3.1

According to the results, the content and release of the drug from the formulation were stable in all storage conditions for the entire testing period. At first, the drug was 100% intact and 75.6% was released at the 72-hour mark. After keeping the product at room temperature (25°C), the drug level decreased by a little to 98.3% and the release of the drug reduced by a small amount to 73.8%. In the same way, keeping the samples at 4°C resulted in 99.1% of the drug remaining and 74.5% being released which is very little degradation. At higher temperatures (40°C) and humidity (75%), the drug content dropped to 95.7% and the drug released decreased to 70.4% which suggests that exposure to heat and humidity harmed stability. All in all, the formulation shows good resistance to changes in storage, making it suitable for everyday pharmaceutical use.

3.6. In Vitro Biological Evaluation

When tested on mammalian cells, the finished formulas had low toxicity and F3 in particular kept cell survival high at over 90% in all the doses tested. The data confirms that the controlled drug delivery systems are biocompatible, so they can be tested in further preclinical and clinical trials.

4. DISCUSSION

4.1. Interpretation of Results

Polymer concentration was found to greatly affect the important aspects of the formulation, like particle size, how well the encapsulation happened and the drug release rate. Products with greater polymer content (F3) showed bigger particles, better drug encapsulation and a longer release time [12]. By using

this method, the drug is released slowly so it stays in your system for a long time which may lead to fewer doses. The DSC analysis showed that the drug was evenly spread inside the polymer matrix as an amorphous form which probably improved its solubility and bioavailability.

4.2. Comparison with Existing Studies

The results are in agreement with previous studies that found raising the polymer concentration makes particles larger and helps improve the encapsulation processs [13]. It has been reported by similar studies that putting drugs in an amorphous state in polymers helps drug dissolution and regulated release [14]. The process of drug release from the polymer is in line with the usual mechanisms described for biodegradable polymer carriers.

4.3. Implications of Findings

Being able to change the polymer concentration to control particle and drug release offers a useful way to design drug delivery systems for various medical needs. Because the formulations are stable in different storage conditions, they can be used in practice and kept for a long time [15]. In addition, since these formulations are not very toxic to cells, they may be safe to use in living organisms and could be good options for further clinical development.

4.4. Limitations of the Study

- The work did not examine the pharmacokinetic and pharmacodynamic effects of the drug in living organisms which is necessary for checking if it is safe and effective.
- As only one drug and polymer were used in the study, the findings may not work for other combinations.
- Researchers did not determine if the formulations would remain biocompatible or trigger immune responses after a long time.
- Different physiological settings and co-existence with biological substances were not studied.

4.5. Suggestions for Future Research

Future studies could perform experiments in living organisms to check if the observed release and safety are the same as in vitro tests. Conducting studies with various drugs that have different physical and chemical properties and using different polymers may broaden the results. Additional work on the recipe and testing in simulated body conditions could add to the understanding of release and help in transferring the work to patients.

5. CONCLUSION

5.1. Summary of Key Findings

It was found that altering the polymer concentration in the study allowed for controlled drug delivery, as the particles became bigger, drug encapsulation was more effective and the release of the drug was sustained as the polymer content increased. Physicochemical tests proved that the drug and polymer are compatible and in vitro studies showed that the release was controlled by both diffusion and erosion of the polymer. Optimized formulation was tested for stability and it was able to maintain the drug content and release rate in different storage conditions. Moreover, the biocompatibility tests indicated that the formulations were safe because of their low cytotoxicity.

5.2. Significance of the Study

The results show that the amount of polymer plays a key role in creating controlled release systems that can raise the effectiveness of a drug by increasing its availability in the body and cutting down on doses.

Since they are stable and biocompatible, these formulations seem suitable for more study and use in clinical settings to solve drug delivery problems.

5.3. Final Thoughts or Recommendations

- It is necessary to do further tests on living animals to confirm the outcomes and safety seen in the lab.
- Try out new drug-polymer pairs to make controlled drug delivery systems more useful.
- Perform research on stability to check whether the formulation remains stable over a long time.
- Tweak the drug's formulation to suit the distinct needs of different patients

REFERENCES

1. Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: current status and future directions. Molecules, 26(19), 5905.
2. Pillai, A., Bhande, D., & Pardhi, V. (2023). Controlled drug delivery system. In Advanced drug delivery: Methods and applications (pp. 267-289). Singapore: Springer Nature Singapore.
3. Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. Signal transduction and targeted therapy, 3(1), 7.
4. Chenthamara, D., Subramaniam, S., Ramakrishnan, S. G., Krishnaswamy, S., Essa, M. M., Lin, F. H., &Qoronfleh, M. W. (2019). Therapeutic efficacy of nanoparticles and routes of administration. Biomaterials research, 23(1), 20.
5. Jeong, W. Y., Kwon, M., Choi, H. E., & Kim, K. S. (2021). Recent advances in transdermal drug delivery systems: A review. Biomaterials research, 25, 1-15.
6. Liu, P., Chen, G., & Zhang, J. (2022). A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules, 27(4), 1372.
7. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., ... & Shin, H. S. (2018). Nano based drug delivery systems: recent developments and future prospects. Journal of nanobiotechnology, 16, 1-33.
8. Jain, K. K. (2019). An overview of drug delivery systems. Drug delivery systems, 1-54.
9. Homayun, B., Lin, X., & Choi, H. J. (2019). Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics, 11(3), 129.
10. Patel, A. V., & Shah, B. N. (2018). TRANSDERMAL DRUG DELIVERY SYSTEM: A REVIEW. Pharma Science Monitor, 9(1).
11. Olusanya, T. O., Haj Ahmad, R. R., Ibegbu, D. M., Smith, J. R., &Elkordy, A. A. (2018). Liposomal drug delivery systems and anticancer drugs. Molecules, 23(4), 907.
12. Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., &Aldughaim, M. S. (2023). Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems. Polymers, 15(7), 1596.
13. Qiu, M., Wang, D., Liang, W., Liu, L., Zhang, Y., Chen, X., ... & Cao, Y. (2018). Novel concept of the smart NIR-light–controlled drug release of black phosphorus nanostructure for cancer therapy. Proceedings of the National Academy of Sciences, 115(3), 501-506.
14. Guo, X., Cheng, Y., Zhao, X., Luo, Y., Chen, J., & Yuan, W. E. (2018). Advances in redox-responsive drug delivery systems of tumor microenvironment. Journal of Nanobiotechnology, 16, 1-10.
15. Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019). Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers, 11(5), 640.